{
  "docId": "019dd923-5ca1-7489-b638-42055a53b541",
  "docSlug": "1774c324fda45105",
  "documentTitle": "Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report",
  "authorId": "LEK",
  "authorName": "L.E.K.",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 24,
  "pageCount": 58,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "industry_trends",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 49,
  "notes": "The chart shows a clear shift in clinical trial focus toward oncology, increasing from 30% in 2016 to 48% in 2022.",
  "elementsJson": [
    "headline_text",
    "action_title",
    "bar_chart_stacked",
    "quote_block",
    "photo",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b638-42055a53b541/24",
  "deckHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-24",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Oncology has become the most heated TA for clinical development in China over the past few years.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cbf-75b60777bb4b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.037,
        "y": 0.215
      },
      "kind": "chart",
      "text": "Number of newly started clinical trials by therapeutic area (2016-2022 Aug.)",
      "attrs": null,
      "subkind": "bar-stacked-100pct",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ab76e5ef-5948-4274-ac37-6bb1009a8802",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.037,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "Note: *Only including phase 1 to phase 3 trials, while excluding BE and TCM trials, phase 4 trials and IITs. Joint clinical trials between MNC and domestic companies are all counted as trials by Chinese company. Source: DXY, L.E.K. analysis",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6856b56c-fdc8-4cb0-9c26-6c80f1c57547",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Number of clinical trials: 48%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cbf-7d871c1d7686",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.42,
        "x": 0.53,
        "y": 0.3
      },
      "kind": "quote",
      "text": "Previously, most players tended to develop products around mature targets and mechanism in oncology area such as PD-1... - Regulatory Lead, a Chinese biopharma, Oct.2022",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "97b60950-8560-4b0f-b95a-a3cbb9b94ae5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.42,
        "x": 0.53,
        "y": 0.55
      },
      "kind": "quote",
      "text": "Oncology drives the past growth of China clinical trials... financial investors prefer to invest in risk-free innovation - President, a Chinese biopharma, Aug. 2021",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f1745d42-d472-41e8-93e3-d48616f71d8f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "Oncology drives the past growth of China clinical trials, because on one hand, traditional pharmas attempt to quickly enter the promising biologics market, however, their 'generic-type' mindset cannot change overnight which has led to much 'fast-follow' - President, a Chinese biopharma, Aug. 2021",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cbf-7beca2a22488",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.85,
        "x": 0.037,
        "y": 0.103
      },
      "kind": "title",
      "text": "Oncology has become the most heated TA for clinical development in China over the past few years",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "88b2d076-3e4c-4223-a8e9-df7f9c5787ed",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [
    {
      "metricRaw": "Number of clinical trials",
      "numberRaw": "48%",
      "numberKind": "percent",
      "actionTitle": "Oncology has become the most heated TA for clinical development in China over the past few years",
      "calloutText": "Oncology has become the most heated TA for clinical development in China over the past few years.",
      "numberScale": null,
      "numberValue": 48,
      "metricFamily": "volume_count",
      "numberCurrency": null
    }
  ],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}